| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2dccae73fc568746ee7a24187042474 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 |
| filingDate |
2021-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57bc34a9722bf8c2334ee5e5c043fc5f |
| publicationDate |
2022-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022133837-A1 |
| titleOfInvention |
Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases |
| abstract |
Peptides and methods of use thereof, are disclosed for use in treating disorders caused by the novel coronavirus SARS-CoV-2 or resulting from COVID-19 disease, such as systemic inflammation or pneumonia. The peptides modulate the activity of the transcription factor NF κB. |
| priorityDate |
2020-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |